Drug Pricing: Page 2

Global Blood's sickle cell drug wins FDA approval, joining Novartis' Adakveo

A list price of roughly $10,000 a month puts Global Blood's Oxbryta slightly higher than what Novartis' Adakveo will cost.

By Jonathan Gardner • UPDATED: Nov. 26, 2019 at 10:04 a.m.

France clears way for wide use of Vertex's Orkambi

By agreeing to reimburse the drug beyond compassionate use, France opens up access to one of the largest cystic fibrosis populations outside the U.S.

By Jonathan Gardner • Nov. 20, 2019

ICER draws new gene therapy pricing framework

One-time and short-term curative therapies require a different approach to evaluating benefit, the cost watchdog group said. 

By Jonathan Gardner • Nov. 13, 2019

Trump administration sues Gilead over HIV drug patents

Accused of unfairly profiting from government research, Gilead said it will ask the district court to stay HHS' suit until the U.S. Patent Office reviews the disputed patents.

By Ned Pagliarulo • UPDATED: Nov. 7, 2019 at 5:43 p.m.

Third Neulasta biosimilar on its way as Sandoz wins long-delayed FDA approval

Novartis' drug will be third to market, but copycat drugs have already taken a chunk of the market away from Amgen's branded version.

By Jonathan Gardner • Nov. 05, 2019

Allergan pays $750M to rid itself of Namenda antitrust charges

A class action suit followed the New York attorney general in claiming the big pharma tried to delay generic competition to its Alzheimer's drug. 

By Jonathan Gardner • Oct. 28, 2019

Pelosi drug plan would save $370B, but could reduce R&D, forecasters say

Pharma would respond to Pelosi's proposal by raising list prices, keeping some drugs off foreign markets, and cutting R&D spending, according to the CBO.

By Jonathan Gardner • Oct. 14, 2019

With new report, ICER puts itself at center of drug pricing storm

Pharma price hikes added billions of dollars to U.S. spending in 2017 and 2018. For seven top drugs, the watchdog found those increases came with little new clinical evidence in support. 

By Ned Pagliarulo • UPDATED: Oct. 8, 2019 at 1:03 p.m.

Buttigieg targets pharma in aggressive plan to lower drug prices

The presidential hopeful supports several policies, such as direct drug price negotiation, that feature in legislation proposed by House Democrats. 

By Ned Pagliarulo • Oct. 07, 2019

Top Pelosi aide to payers: Help us defeat Big Pharma

Wendell Primus' pitch sparked debate between policy experts and industry representatives Monday at AHIP's annual conference.

By Samantha Liss • Sept. 24, 2019

States pull back curtain on drug prices, to uncertain effect

A newly enacted law in Colorado requires pharma companies inform doctors of list prices, as well as the names of three generics in the same treatment class. 

By Ned Pagliarulo • Sept. 23, 2019

Novo gains approval for first oral diabetes drug of its kind

The list price for Rybelsus will be competitive within the GLP-1 drug class, Novo said, which may make it more expensive than other glucose-lowering pills.

By Jonathan Gardner • UPDATED: Sept. 24, 2019 at 4:32 p.m.

The top drugs facing cuts under Pelosi's pricing plan

Democrats' plan would put pressure on top-sellers from Bristol-Myers Squibb, Regeneron and Merck & Co, among others.

By Jonathan Gardner • Sept. 20, 2019

House Democrats forge ahead with direct Medicare drug price negotiation

While drug price constraints may still become law, House Speaker Nancy Pelosi's proposal looks like a long shot.

By Jonathan Gardner • Sept. 19, 2019

Regulatory barriers limit alternative state drug payment models

Forced to balance higher costs with public health goals, more states are looking at alternative payment models for prescription drugs in Medicaid.

By Samantha Liss • Sept. 18, 2019

Deep Dive

Public trust in drugmakers is at an all-time low. Can biopharma recover?

Leaders are grappling with how to improve the industry's reputation at a time when the broader business world is under increased scrutiny.

By Andrew Dunn • Sept. 11, 2019

ICER dings Novo's new oral diabetes drug

The semaglutide pill is less effective than Jardiance and more expensive if priced similarly to the drug's injectable form, ICER said in a draft report.

By Jonathan Gardner • Sept. 11, 2019

Medicare would negotiate prices for 250 drugs under House Democrats' plan

Speaker Nancy Pelosi's proposal also finds common ground with the president in pegging U.S. prices to an international index.

By Jonathan Gardner • Sept. 10, 2019

Deep Dive

Unblinded: Rebekah Gee's drug pricing experiment in Louisiana

Louisiana's health secretary negotiated a new payment model with Gilead for one of the poorest states in the country. Could it spread nationwide?

By Andrew Dunn • Aug. 28, 2019

Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds

Out-of-pocket spending on MS medications increased by more than 600% in the decade from 2006 to 2016, while the typical list price quadrupled.

By Andrew Dunn • Aug. 27, 2019

Congress is going after drug prices. Pharma CEOs aren't panicking, yet

A Senate Finance bill could emerge as the most palatable option for an industry seeking to limit losses in an election cycle already targeting pricing as an issue.

By Ned Pagliarulo • Aug. 02, 2019

Medicines Co. awaits its date with destiny

After slimming down to focus on one big R&D bet, the company needs inclisiran to match or outperform on-market PCSK9 drugs Repatha and Praluent.

By Jonathan Gardner • Aug. 01, 2019

Teva, Endo among generics paying $70M in California pay-for-delay settlement

The state accused Teva, Endo and Japan-based Teikoku of anticompetitive practices on two drugs, which it said drove healthcare costs higher.

By Jacob Bell • July 29, 2019

Senate advances drug pricing bill, setting up September vote

PhRMA's CEO, along with a number of drugmaker executives, met with President Trump this week to lay out their opposition to the bill. 

By Jonathan Gardner • July 26, 2019

Senate committee targets drug price increases with broad bill

Legislation is newly in focus after the White House dropped a bid to ban certain Medicare rebates, and saw another pricing plan defeated in court.

By Jonathan Gardner • July 23, 2019